Treatments

Inside the First FDA-Approved CAR T-Cell Therapy

ALL patients who haven’t responded to standard care have new options on the horizon, including a type of immunotherapy called CAR T-cell therapy. Learn more from Dr. Michael Deininger.

Andrew Schorr, Michael Deininger, MD, PhD

How Can Acute Lymphoblastic Leukemia Treatment Be Tailored?

Dr. Elias Jabbour from The University of Texas MD Anderson Cancer Center explains how patient's individual circumstances affect treatment decisions. Watch to learn from an ALL expert.

Dr Elias Jabbour

Latest News

Multi-Agent Therapies for Acute Lymphoblastic Leukemia

Gail J. Roboz, MD, Ruth Fein

Treating Adult, Adolescent and Pediatric Acute Lymphoblastic Leukemia (ALL)

Gail J. Roboz, MD, Ruth Fein

Current Treatments for Adult Acute Lymphoblastic Leukemia

Gail J. Roboz, MD, Ruth Fein

Acute Lymphoblastic Leukemia Treatment During Coronavirus Outbreak

Gail J. Roboz, MD, Ruth Fein

Immunotherapy and Chemotherapy for Pediatric ALL

Andrew Schorr, Allison Grimes, MD

Acute Lymphoblastic Leukemia in Children Versus Adults

Lauren Evoy Davis

Confidence in Your Care: A Team Approach to Treating ALL

Jud Logan, Andrew Schorr, Hetty Carraway, MD

Treatments for ALL: Chemo and Beyond

Ryan Cassaday, MD, Andrew Schorr

The Science Behind Immunotherapy for ALL

Patrick Brown, MD, Esther Schorr

Antibodies, Immunotherapy and Clinical Trials

Shira Dinner, MD, Esther Schorr

Do ALL Treatments Depend on Age?

Esther Schorr, Patrick Brown, MD

ALL Clinical Trial Shows Promise in Young Adults

Patrick Brown, MD, Esther Schorr